JP2020509031A5 - - Google Patents

Download PDF

Info

Publication number
JP2020509031A5
JP2020509031A5 JP2019547310A JP2019547310A JP2020509031A5 JP 2020509031 A5 JP2020509031 A5 JP 2020509031A5 JP 2019547310 A JP2019547310 A JP 2019547310A JP 2019547310 A JP2019547310 A JP 2019547310A JP 2020509031 A5 JP2020509031 A5 JP 2020509031A5
Authority
JP
Japan
Prior art keywords
preparation according
monoclonal antibody
seq
concentration
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019547310A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020509031A (ja
JP7046088B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/020264 external-priority patent/WO2018160722A1/en
Publication of JP2020509031A publication Critical patent/JP2020509031A/ja
Publication of JP2020509031A5 publication Critical patent/JP2020509031A5/ja
Priority to JP2022045862A priority Critical patent/JP7446356B2/ja
Application granted granted Critical
Publication of JP7046088B2 publication Critical patent/JP7046088B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019547310A 2017-03-01 2018-02-28 抗ｒｓｖモノクローナル抗体製剤 Active JP7046088B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022045862A JP7446356B2 (ja) 2017-03-01 2022-03-22 抗ｒｓｖモノクローナル抗体製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762465379P 2017-03-01 2017-03-01
US62/465,379 2017-03-01
PCT/US2018/020264 WO2018160722A1 (en) 2017-03-01 2018-02-28 Anti-rsv monoclonal antibody formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022045862A Division JP7446356B2 (ja) 2017-03-01 2022-03-22 抗ｒｓｖモノクローナル抗体製剤

Publications (3)

Publication Number Publication Date
JP2020509031A JP2020509031A (ja) 2020-03-26
JP2020509031A5 true JP2020509031A5 (https=) 2021-03-04
JP7046088B2 JP7046088B2 (ja) 2022-04-01

Family

ID=61903153

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019547310A Active JP7046088B2 (ja) 2017-03-01 2018-02-28 抗ｒｓｖモノクローナル抗体製剤
JP2022045862A Active JP7446356B2 (ja) 2017-03-01 2022-03-22 抗ｒｓｖモノクローナル抗体製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022045862A Active JP7446356B2 (ja) 2017-03-01 2022-03-22 抗ｒｓｖモノクローナル抗体製剤

Country Status (24)

Country Link
US (4) US10774133B2 (https=)
EP (1) EP3589648A4 (https=)
JP (2) JP7046088B2 (https=)
KR (2) KR102668158B1 (https=)
CN (3) CN117982637A (https=)
AR (1) AR111083A1 (https=)
AU (2) AU2018227502B2 (https=)
BR (1) BR112019017755A2 (https=)
CA (1) CA3051864A1 (https=)
CL (1) CL2019002478A1 (https=)
CO (1) CO2019009034A2 (https=)
CR (1) CR20190400A (https=)
EA (1) EA201991701A1 (https=)
EC (1) ECSP19062769A (https=)
GB (1) GB2564175B (https=)
IL (2) IL312499A (https=)
MX (1) MX2019010408A (https=)
MY (1) MY206022A (https=)
PH (1) PH12019501979A1 (https=)
SG (1) SG11201906853QA (https=)
TW (2) TWI761453B (https=)
UA (1) UA128450C2 (https=)
WO (1) WO2018160722A1 (https=)
ZA (1) ZA202006797B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
ES2795727T3 (es) 2014-01-15 2020-11-24 Medimmune Llc Anticuerpos específicos del vrs y partes funcionales de los mismos
EP3383435A4 (en) * 2015-11-30 2019-07-10 Medimmune, LLC OPTIMIZED RATES OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS HAVING HIGH CONCENTRATIONS IN PROTEIN-BASED THERAPEUTICS
TWI761453B (zh) * 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
BR112019018022A2 (pt) * 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2020081408A1 (en) 2018-10-18 2020-04-23 Merck Sharp & Dohme Corp. Formulations of anti-rsv antibodies and methods of use thereof
MX2021004928A (es) 2018-10-31 2021-06-08 Merck Sharp & Dohme Llc Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
EP3876990A4 (en) 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
CN113993884A (zh) * 2019-04-18 2022-01-28 弗劳恩霍夫应用研究促进协会 抑制呼吸道合胞病毒感染的生物及合成分子
US12024553B2 (en) * 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies
HRP20240182T1 (hr) 2020-03-26 2024-04-26 Vanderbilt University Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
JP2023537316A (ja) * 2020-07-31 2023-08-31 アラマブ セラピューティクス， インコーポレイテッド 抗コネキシン抗体製剤
CN115960214A (zh) * 2021-10-12 2023-04-14 中国科学院分子细胞科学卓越创新中心 中和呼吸道合胞病毒的全人抗体的设计及应用
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
CN119264248A (zh) * 2022-07-22 2025-01-07 北京智仁美博生物科技有限公司 抗呼吸道合胞病毒中和性抗体及其用途
EP4588936A1 (en) * 2022-12-08 2025-07-23 Changchun Bcht Biotechnology Co. Antibodies specifically binding to rsv

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
DE69609188T2 (de) 1995-09-18 2000-12-21 Intracel Corp., Issaquah Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
AU2013201261B2 (en) * 2002-06-14 2016-06-23 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
MXPA05010555A (es) * 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
JP2009532336A (ja) * 2006-03-06 2009-09-10 メディミューン，エルエルシー ヒト化抗ｃｄ２２抗体、並びに腫瘍、移植及び自己免疫疾患の治療におけるこれらの使用
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US9011876B2 (en) 2008-11-05 2015-04-21 Merck Sharp & Dohme Corp. Live, attenuated respiratory syncytial virus
EP2458990B1 (en) * 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
EP2486053B1 (en) 2009-10-06 2017-01-18 Medimmune Limited Rsv-specific binding molecule
CL2011003002A1 (es) 2011-11-25 2012-05-25 Univ Pontificia Catolica Chile Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento.
EP4527855A3 (en) * 2012-03-26 2025-06-11 Sanofi Stable igg4 based binding agent formulations
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
CA2900110A1 (en) 2013-02-01 2014-08-07 Medimmune, Llc Respiratory syncytial virus f protein epitopes
ES2795727T3 (es) * 2014-01-15 2020-11-24 Medimmune Llc Anticuerpos específicos del vrs y partes funcionales de los mismos
CN107073113A (zh) * 2014-10-18 2017-08-18 辉瑞大药厂 抗il‑7r抗体组合物
EA039065B1 (ru) * 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
TWI761453B (zh) * 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
BR112019018022A2 (pt) * 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais
US12024553B2 (en) * 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies

Similar Documents

Publication Publication Date Title
JP2020509031A5 (https=)
JP2024016177A5 (https=)
US20240182573A1 (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
JP2020518599A5 (https=)
CN110418803B (zh) 抗rsv单克隆抗体配制品
JP2020518600A5 (https=)
JP6647208B2 (ja) 抗ｉｌ−１７抗体、その生産および使用のための方法
JP2022079549A5 (https=)
CN111971062A (zh) 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
JP2023109942A5 (https=)
JP2020518598A5 (https=)
JP2023515271A5 (https=)
JP2018535650A5 (https=)
FI4045533T3 (fi) Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
JP2018188437A5 (https=)
JP2019163319A5 (https=)
JP2019031565A5 (https=)
HRP20201345T1 (hr) Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba
JP2017160208A5 (https=)
JP2021527640A5 (https=)
CN112741804A (zh) 含有抗pd-l1抗体的稳定制剂
JP2025032102A5 (https=)
KR20160079890A (ko) 항체-약물 접합체 동결건조 제제
JP2024508762A5 (https=)
JP2016534052A5 (https=)